Table 1.
Demographic and clinical characteristics for subjects stratified by baseline sputum differential groups at enrollment (Baseline) and over the following 3 years.
| Label | Low Eos+Low Neu | Low Eos+High Neu | High Eos+Low Neu | High Eos+High Neu | P value across 4 Eos+Neu groups |
|---|---|---|---|---|---|
| N Baseline | 101 | 130 | 46 | 52 | |
| N year 1 | 95 | 120 | 44 | 47 | |
| N year 2 | 88 | 112 | 43 | 40 | |
| N year 3 | 83 | 103 | 38 | 39 | |
| Age at Baseline | 42.3 ± 13.8 | 49.1 ± 14.3 | 45.6 ± 13.0 | 50.9 ± 13.4 | 0.0006a,f |
| Years since diagnosis of asthma | 23.3 ± 14.0 | 29.7 ± 16.1 | 24.8 ± 13.0 | 30.0 ± 16.5 | 0.0107a,f |
| BMI - Baseline | 34.1 ± 8.7 | 32.5 ± 9.6 | 31.4 ± 8.8 | 31.8 ± 8.9 | 0.0625d,f |
| -year 1 | 34.3 ± 8.9 | 32.3 ± 9.3 | 31.2 ± 8.3 | 30.4 ± 6.7 | 0.0358a,d,f |
| -year 2 | 33.7 ± 8.0 | 32.5 ± 9.5 | 30.5 ± 7.0 | 30.6 ± 7.2 | 0.0686a,d,f |
| -year 3 | 33.7 ± 8.0 | 32.6 ± 9.4 | 30.4 ± 7.5 | 30.6 ± 7.0 | 0.0767a,d |
| Male sex N (%) | 35 (34.7%) | 48 (36.9%) | 12 (26.1%) | 25 (48.1%) | 0.1509 |
| Race %White/%Black/%Other | 63.4/25.7/10.9 | 70/23.1/6.9 | 63/21.7/15.2 | 53.8/25/21.2 | 0.2235/0.9433/0.0451b |
| Severe N (%)(by ATS criteria) Baseline | 51 (50.5%) | 60 (46.2%) | 27 (58.7%) | 31 (59.6%) | 0.2794 |
| -year 1 | 48 (50.5%) | 45 (37.5%) | 18 (40.9%) | 26 (55.3%) | 0.1024 |
| -year 2 | 46 (52.3%) | 38 (33.9%) | 19 (44.2%) | 20 (50%) | 0.0550 |
| -year 3 | 33 (39.8%) | 36 (35%) | 16 (42.1%) | 16 (41%) | 0.8222 |
| Ever smoked N (%) | 24 (23.8%) | 32 (24.6%) | 14 (30.4%) | 20 (38.5%) | 0.2052 |
| PreBD FEV1 %Predicted - baseline | 75.8 ± 18.5 | 76.1 ± 18.5 | 74.8 ± 17.7 | 68.9 ± 19.2 | 0.0721a,b |
| -year 1 | 77.3 ± 17.4 | 76.7 ± 19.9 | 73.7 ± 19.1 | 68.6 ± 21.8 | 0.0394a,b |
| -year 2 | 78.3 ± 18.8 | 76.2 ± 20.5 | 75.3 ± 21.2 | 66.9 ± 20.5 | 0.0194a,b |
| -year 3 | 77.8 ± 17.5 | 76.4 ± 19.2 | 75.2 ± 19.9 | 69.8 ± 21.5 | 0.1335a |
| PostBD FEV1 %Predicted - baseline | 87.6 ± 16.8 | 85.6 ± 17.9 | 88.4 ± 16.9 | 81.1 ± 18.8 | 0.0807a,c |
| -year 1 | 86.9 ± 16.0 | 84.0 ± 19.5 | 87.2 ± 18.4 | 80.3 ± 19.9 | 0.1741a |
| -year 2 | 87.6 ± 16.8 | 84.3 ± 19.4 | 89.8 ± 17.4 | 78.1 ± 19.4 | 0.0123a,b,c |
| -year 3 | 87.6 ± 16.4 | 84.4 ± 18.5 | 89.6 ± 18.8 | 79.5 ± 21.3 | 0.0593a,c |
| PreBD FEV1/FVC Baseline | 0.71 ± 0.10 | 0.71 ± 0.10 | 0.68 ± 0.08 | 0.65 ± 0.10 | 0.0001a,b,e |
| -year 1 | 0.71 ± 0.09 | 0.71 ± 0.10 | 0.68 ± 0.08 | 0.64 ± 0.10 | 0.0001a,b,c |
| -year 2 | 0.71 ± 0.10 | 0.71 ± 0.11 | 0.68 ± 0.10 | 0.64 ± 0.10 | 0.0008a,b,e |
| -year 3 | 0.71 ± 0.09 | 0.71 ± 0.10 | 0.67 ± 0.09 | 0.65 ± 0.11 | 0.0019a,b,d,e |
| Triamcinolone response: Absolute change in Pre-BD FEV %predicted at baseline | 2.1 ± 8.9 | 1.8 ± 6.3 | 3.7 ± 10.4 | 5.0 ± 8.9 | 0.0790b |
| FeNO - Baseline | 20.0 (12.0, 34.0) | 19.0 (13.0, 29.5) | 35.0 (20.0, 53.0) | 26.5 (16.0, 43.5) | 0.0004b,d,e |
| -year 1 | 19.0 (14.0, 33.0) | 19.0 (13.0, 29.0) | 28.0 (19.0, 49.0) | 38.0 (17.0, 55.0) | 0.0002a,b,d,e |
| -year 2 | 21.0 (14.0, 32.0) | 19.5 (12.0, 33.0) | 45.5 (26.0, 73.0) | 30.5 (17.0, 57.5) | <0.0001a,b,d,e |
| Sputum Eosinophils (percent) Baseline | 0.3 (0.0, 0.7) | 0.3 (0.0, 0.9) | 5.6 (2.6, 16.7) | 5.6 (3.6, 8.6) | <0.0001a,b,d,e |
| -year 1 | 0.5 (0.0, 1.1) | 0.4 (0.0, 1.3) | 2.6 (0.6, 17.6) | 4.7 (2.0, 12.0) | <0.0001a,b,d,e |
| -year 2 | 0.4 (0.0, 1.4) | 0.5 (0.0, 1.7) | 5.1 (0.8, 16.7) | 2.7 (1.2, 14.7) | <0.0001a,b,d,e |
| -year 3 | 0.2 (0.0, 0.9) | 0.2 (0.0, 0.9) | 2.7 (1.0, 11.6) | 3.1 (0.2, 11.5) | <0.0001a,b,d,e |
| Sputum Neutrophils (percent) Baseline | 28.6 (16.2, 39.3) | 74.5 (61.9, 87.5) | 35.2 (24.3, 42.6) | 70.8 (60.0, 78.6) | <0.0001a,c,d,e,f |
| -year 1 | 38.3 (21.2, 62.6) | 66.3 (46.5, 80.5) | 49.3 (29.0, 58.3) | 64.8 (49.3, 80.1) | <0.0001a,c,e,f |
| -year 2 | 49.2 (27.8, 59.5) | 69.5 (50.0, 85.1) | 44.8 (29.9, 54.9) | 57.5 (48.9, 69.5) | <0.0001a,c,e,f |
| -year 3 | 53.4 (38.9, 70.3) | 66.3 (55.6, 81.9) | 51.8 (40.9, 69.5) | 67.6 (53.8, 83.0) | 0.0012a,c,e,f |
| Blood Eosinophils (count) Baseline | 168 (105, 255) | 168 (108, 281) | 343 (222, 544) | 344 (224, 489) | <0.0001a,b,d,e |
| Blood Neutrophils (count) Baseline | 4,064 (3,045, 5,188) | 3,949 (3,100, 4,988) | 4,011 (3,180, 5,317) | 3,996 (3,025, 5,857) | 0.9394 |
| Total IgE Baseline Geometric means | 129.3 ± 3.7 | 87.2 ± 5.7 | 199.4 ± 3.8 | 166.8 ± 4.8 | 0.0246b,e |
| At Least One + Specific IgE | 84 (84%) | 103 (80.5%) | 36 (78.3%) | 38 (73.1%) | 0.4472 |
| Number of + Specific IgE tests (of 15) | 4.6 ± 3.7 | 4.1 ± 3.8 | 5.1 ± 4.6 | 4.0 ± 4.0 | 0.3855 |
a
High Eos+High Neu vs Low Eos+Low Neu, p<0.05
b
High Eos+High Neu vs Low Eos+High Neu, p<0.05
c
High Eos+High Neu vs High Eos+Low Neu, p<0.05
d
High Eos+Low Neu vs Low Eos+Low Neu, p<0.05
e
High Eos+Low Neu vs Low Eos+High Neu, p<0.05
f
Low Eos+High Neu vs Low Eos+Low Neu, p<0.05